Scott Akamine - Dec 5, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 5, 2023
Transactions value $
-$445,725
Form type
4
Date filed
12/7/2023, 07:45 PM
Previous filing
Feb 8, 2023
Next filing
Dec 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $98.8K +7.5K +1461.99% $13.17 8.01K Dec 5, 2023 Direct F1, F2
transaction CERE Common Stock Sale -$263K -7.5K -93.6% $35.00 513 Dec 5, 2023 Direct F1
transaction CERE Common Stock Options Exercise $132K +10K +1949.32% $13.17 10.5K Dec 7, 2023 Direct F1
transaction CERE Common Stock Sale -$414K -10K -95.12% $41.37 513 Dec 7, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -7.5K -2.76% $0.00 264K Dec 5, 2023 Common Stock 7.5K $13.17 Direct F1, F3
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10K -3.78% $0.00 254K Dec 7, 2023 Common Stock 10K $13.17 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
F2 Includes 513 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
F3 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.